GSK

GSK· Health · 6 sources · Sep 28, 2026Story

HUTCHMED Begins Global Phase Ia HMPL-A830 Trial

HUTCHMED has begun the Phase Ia portion of a global first-in-human trial of HMPL-A830 in patients with advanced or metastatic solid tumors, with the first dose given in China on September 24. The antibody-targeted therapy is designed to deliver a KRAS inhibitor to EGFR-expressing tumors while blocking both KRAS and EGFR signaling; the early-stage study will assess safety, dosing and preliminary anti-tumor activity.

Health· Sep 28, 2026

GSK· Business · 16 sources · Sep 3, 2026Story

GSK pays Hutchmed $110M upfront in deal worth up to $1.3B

GSK agreed to license Hutchmed’s HMPL-A830, a KRAS-EGFR antibody-drug conjugate, for up to $1.295 billion including $110 million upfront, with global rights outside Mainland China, Hong Kong, Macau and Taiwan while Hutchmed retains development and commercialization duties in those regions. The collaboration targets initial trials in colorectal, pancreatic, and lung cancers, leveraging a dual KRAS-EGFR mechanism to improve efficacy and tolerability.

Business· Sep 3, 2026

GSK· Health · 9 sources · Jul 23, 2026Story

GSK earns FDA approval for Jideytro

GSK won FDA approval for Jideytro (zidesamtinib), its ROS1 inhibitor for ROS1-positive non-small cell lung cancer, ahead of the September 18 deadline as part of its Nuvalent acquisition. The treatment, showing a 44% response rate in trials, positions GSK to compete in lung cancer and supports ongoing development of additional Nuvalent assets like neladalkib and ris-rez.

Health· Jul 23, 2026

HUTCHMED Begins Global Phase Ia HMPL-A830 Trial

GSK pays Hutchmed $110M upfront in deal worth up to $1.3B

GSK earns FDA approval for Jideytro

GSK

HUTCHMED Begins Global Phase Ia HMPL-A830 Trial

GSK pays Hutchmed $110M upfront in deal worth up to $1.3B

GSK earns FDA approval for Jideytro

GSK across IJR

Related journals

Miembros destacados

GSK across IJR

Últimas noticias y debate sobre GSK

HUTCHMED Begins Global Phase Ia HMPL-A830 Trial

GSK pays Hutchmed $110M upfront in deal worth up to $1.3B

GSK earns FDA approval for Jideytro

Últimas noticias y debate sobre GSK

HUTCHMED Begins Global Phase Ia HMPL-A830 Trial

GSK pays Hutchmed $110M upfront in deal worth up to $1.3B

GSK earns FDA approval for Jideytro

GSK across IJR

Related journals

Miembros destacados

GSK across IJR